Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy EyePoint Pharmaceuticals stock | $4.49

Own EyePoint Pharmaceuticals stock in just a few minutes.

Fact checked

EyePoint Pharmaceuticals, Inc is a biotechnology business based in the US. EyePoint Pharmaceuticals shares (EYPT) are listed on the NASDAQ and all prices are listed in US Dollars. EyePoint Pharmaceuticals employs 84 staff and has a trailing 12-month revenue of around USD$35.9 million.

How to buy shares in EyePoint Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for EyePoint Pharmaceuticals. Find the stock by name or ticker symbol: EYPT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until EyePoint Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$4.49, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of EyePoint Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of EyePoint Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

EyePoint Pharmaceuticals share price

Use our graph to track the performance of EYPT stocks over time.

EyePoint Pharmaceuticals shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$4.49
52-week rangeUSD$3.511 - USD$21
50-day moving average USD$4.585
200-day moving average USD$5.7864
Wall St. target priceUSD$22.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.721

Buy EyePoint Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Forex
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Public
$0
Stocks, ETFs
N/A
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy EyePoint Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

EyePoint Pharmaceuticals price performance over time

Historical closes compared with the close of $4.49 from 2020-12-09

1 week (2021-01-14) -59.00%
1 month (2020-12-24) -10.02%
3 months (2020-10-22) 858.99%
6 months (2020-07-22) 497.95%
1 year (2020-01-22) 178.88%
2 years (2019-01-22) 97.80%
3 years (2018-01-22) 308.18%
5 years (2016-01-22) 25.77%

EyePoint Pharmaceuticals financials

Revenue TTM USD$35.9 million
Gross profit TTM USD$2.3 million
Return on assets TTM -26.42%
Return on equity TTM -342.81%
Profit margin -112.23%
Book value $0.578
Market capitalisation USD$71.5 million

TTM: trailing 12 months

Shorting EyePoint Pharmaceuticals shares

There are currently 348,813 EyePoint Pharmaceuticals shares held short by investors – that's known as EyePoint Pharmaceuticals's "short interest". This figure is 66.7% up from 209,255 last month.

There are a few different ways that this level of interest in shorting EyePoint Pharmaceuticals shares can be evaluated.

EyePoint Pharmaceuticals's "short interest ratio" (SIR)

EyePoint Pharmaceuticals's "short interest ratio" (SIR) is the quantity of EyePoint Pharmaceuticals shares currently shorted divided by the average quantity of EyePoint Pharmaceuticals shares traded daily (recently around 198189.20454545). EyePoint Pharmaceuticals's SIR currently stands at 1.76. In other words for every 100,000 EyePoint Pharmaceuticals shares traded daily on the market, roughly 1760 shares are currently held short.

However EyePoint Pharmaceuticals's short interest can also be evaluated against the total number of EyePoint Pharmaceuticals shares, or, against the total number of tradable EyePoint Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case EyePoint Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 EyePoint Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0322% of the tradable shares (for every 100,000 tradable EyePoint Pharmaceuticals shares, roughly 32 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against EyePoint Pharmaceuticals.

Find out more about how you can short EyePoint Pharmaceuticals stock.

EyePoint Pharmaceuticals share dividends

We're not expecting EyePoint Pharmaceuticals to pay a dividend over the next 12 months.

Have EyePoint Pharmaceuticals's shares ever split?

EyePoint Pharmaceuticals's shares were split on a 1:10 basis on 9 December 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your EyePoint Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for EyePoint Pharmaceuticals shares which in turn could have impacted EyePoint Pharmaceuticals's share price.

EyePoint Pharmaceuticals share price volatility

Over the last 12 months, EyePoint Pharmaceuticals's shares have ranged in value from as little as $3.511 up to $21. A popular way to gauge a stock's volatility is its "beta".

EYPT.US volatility(beta: 1.51)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while EyePoint Pharmaceuticals's is 1.5144. This would suggest that EyePoint Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

EyePoint Pharmaceuticals overview

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. The company provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery; and Retisert, a sustained-release implant for the treatment of posterior segment uveitis. It is also developing EYP-1901, a 6-month bioerodible Durasert Vorolanib tyrosine kinase inhibitor, for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. The company also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site